Annovis Bio (ANVS) News
NYSE: ANVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.7113-0.0371 (-4.96%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANVS news summary
We found 11 recent headlines mentioning Annovis Bio (ANVS): 3 in the past week and 10 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, ANVS is down 4.96% at $0.7113. The most recent story, "Annovis Bio To Pool Safety Data From Four Buntanetap Studies Following FDA Agreement", was published by Nasdaq on Nov 20, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Annovis Bio headlines
- Annovis Bio To Pool Safety Data From Four Buntanetap Studies Following FDA Agreement(RTTNews) - Annovis Bio Inc. (ANVS) announced that the U.S. FDA has agreed to its Integrated Summary of Safety (ISS) plan for buntanetap, an investigational oral therapy being developed for…NasdaqANVS, UHAL.B
- Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDAMALVERN, Pa., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational…GlobeNewswire
- Annovis Receives Second Positive DSMB Recommendation for its Phase 3 DUET-AD StudyMALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational…GlobeNewswire
- Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial ResultsMALVERN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing buntanetap, an investigational…GlobeNewswire
- Annovis Closes $21 Million Offering, Funds Operations Through Phase 3 Alzheimer's Readout; Stock Up(RTTNews) - Annovis Bio (ANVS), clinical-stage biotechnology company developing treatments for neurodegenerative diseases, announced the completion of a $21.0 million underwritten public offering,…NasdaqANVS, MOG.A
- Annovis Announces Pricing of $21.0 Million Public OfferingMALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…GlobeNewswire
- Annovis Bio, Inc. Reports Preliminary Cash and Cash Equivalents of approximately $2.8 millionAnnovis Bio, Inc. provided preliminary estimates regarding its cash and cash equivalents as of September 30, 2026. Based on currently available information, the company estimates that its cash and…Nasdaq
- Annovis Bio, Inc. Stockholders Approve Increase in Authorized Shares to 140,000,000Annovis Bio, Inc. held its Special Meeting of Stockholders telephonically on November 3, 2026. At the meeting, stockholders approved an amendment to the Company’s Amended and Restated…Nasdaq
- Annovis Announces Launch of Proposed Public OfferingMALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…GlobeNewswire
- Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSEMALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral…GlobeNewswire
- Weekly Buzz: MESO, LLY, ANIP Win FDA Nod; KALA, HCTI Sign LOI; IMVT Halts Lupus Study(RTTNews) - Biotech and pharma companies delivered a busy slate of updates, spanning regulatory approvals, multibillion-dollar drug discovery partnerships and pivotal clinical-trial readouts across…NasdaqABBV, ABEO, AMRX, ANIP